Dealings in Clinigen shares are expected to commence on AIM at 8.00am on Tuesday 25 September 2012, under the ticker symbol CLIN





Clinigen is a rapidly-growing specialty pharmaceutical and services company, with one clear aim: to deliver the right drug to the right patient at the right time.




To achieve our aim, we have built a group of complementary businesses which can operate efficiently in a complex global regulatory environment and which can ensure that precious medicines are delivered securely and effectively, wherever they are needed. Through three businesses, Clinigen SP, Clinigen GAP, and Clinigen CTS, we acquire, license and revitalise niche, hospital-only critical care medicines, and source and supply our own and other pharmaceutical companies’ products, whether to meet unmet medical needs or for use in clinical trials.





Clinigen Clinical Trials Supply (CTS):

We use our global expertise, systems and relationships to source and manage the supply of commercial medicines to pharmaceutical companies for use exclusively in clinical trials. This requires excellent knowledge of the global pharmaceutical market, the regulatory processes and customs authorities of countries all over the world, along with a high tech supply chain with guaranteed quality and safety standards that can deliver swiftly.

Clinigen Global Access Programs (GAP):

On behalf of pharmaceutical and biotech companies, we manage essential programs that provide access to critical medicines for physicians and their patients all over the world. But what is a Global Access Program? Known by many terms from ‘expanded access’ and ‘named patient’ to ‘compassionate use’ and ‘early access’, a global access program enables physicians to access treatments that are not available in their own country for patients with an unmet medical need. Wherever they are, we can deliver treatments quickly, efficiently and, most importantly, ethically.

Clinigen Specialty Pharmaceuticals (SP):

We acquire niche medicines that don’t fit into the portfolio of larger pharmaceutical companies. These are typically hospital-only treatments for rare or life-threatening diseases, and we specialise in revitalising them – finding new treatment areas; new markets where we can get them licensed; or, potentially, new formulations. All the while, we’re ensuring that patients already using the medicine continue to get the treatment they need, while the company whose product we have acquired can feel confident that its reputation is being well looked after.

We are currently 100+ people, headquartered in Burton-on-Trent in the UK, with facilities in Philadelphia, US, and Tokyo, Japan, and an office in London. With a customer services team who speak over 19 languages between them, our clients from all over the world find us easy to do business with, while doctors and pharmacists find us a valuable source of information about how to access the medicines they need for their patients.




http://www.clinigen.co.uk/

The I. C. article;

Buy ahead of Clinigen re-rating
Bull points
High margins Undervalued Experienced management Strong order book
Bear points
Lumpy revenue stream Disappointing 2013
After listing in late 2012, pharmaceutical group Clinigen (CLIN) fast become the darling of London’s junior Aim market. The listing price – 164p
– surged to 690p early this year but some disappointments in half-year results in February led to a substantial share price fall. But with strong full-year numbers looking likely when the company reports its figures later this month, we think there is now considerable ground to make up on the upside. Investors therefore have a second opportunity to buy the stock, this time at a significant discount to 2013 levels.
There are two main reasons Clinigen won rapturous support from investors when it arrived on the London Stock Exchange. The clinical trials market into which Clinigen supplies third-party material is growing at about 15 per cent a year. Secondly, Clinigen’s management had a proven track record in understanding the complex regulation surrounding specialist access to certain drugs – encompassed by its global access programme (GAP) division.
But at the start of 2014, when Clinigen released half-year results for the six months to December, concerns started to build about the shares overheating. The clinical trial supply (CTS) division – responsible for more than 64 per cent of first-half sales – revealed a 13 per cent fall in sales to £39.5m, and it didn’t help that management admitted that a near four percentage point rise in the CTS gross profit margin – to 16.5 per cent – was ‘unsustainable’. Consequently, the shares crashed 17 per cent on the morning the news came out.
But the company still holds substantial promise for future growth and increasing shareholder returns. The specialty pharmaceuticals division, which provides a solid backbone and accounted for just over half gross profits for the first six months of the year, is still in an early stage of development, with management aiming to add six new drugs over the next three to five years. Meanwhile, the CTS segment is forecast to grow 5 per cent in 2015, and GAP, which accounted for 16 per cent of first-half sales, continues to be Clinigen’s fastest-growing division.
Encouragingly, chief executive Peter George says the lumpy nature of the CTS business and the drop in half-year sales was solely the result of strong comparative figures last year, which included a large number of low-margin anti-viral study sales. He also believes an overdependence on CTS revenues as the bulk of sales will soon be a thing of the past.
A bullish trading update released at the end of July has already begun the re-rating of the stock. In it, Clinigen said it expects like-for-like sales growth of more than 7 per cent for 2014, with total revenues of no less than £126m. The GAP division is expected to report 50 per cent sales growth, and CTS should see revenues up more than 11 per cent in the second half compared with the first half.
Continued improvement in gross margins across all the divisions also contributed to a 17 per cent improvement in underlying cash profits as at the end of June, suggesting full-year results should beat analysts’ expectations. Such a solid performance could be down to lower operational costs, and the keen prices paid for two newly acquired speciality pharma drugs: Cardioxane and Savene. And management says there is also potential in Clinigen’s new business pipeline for CTS and GAP, which broker N+1 Singer puts at about £200m.
Come the 2014 annual results on 24 September, investors should glean further clarity on Clinigen’s new business pipeline and how the new speciality pharma products will help drive growth. This could provide the re-rating catalyst the stock needs. We think investors would do well to boost their stake in Clinigen while the shares trade on 16 times 2015 earnings. Buy. HR

After losing its ‘hot stock’ status at the time of its half-year results in February, Clinigen looks set to re-rate

Cheers g. :-)

Clinigen Launch Antibiotic, Vibativ in Europe

RNS


RNS Number : 0710S

Clinigen Group plc

18 September 2014






Clinigen Group launches New First-in-Class Antibiotic VIBATIV® (telavancin) for MRSA related Hospital-Acquired Pneumonia across Europe



Burton-on-Trent, UK - 18 September 2014 - Clinigen Group plc ('Clinigen' or the 'Group') (AIM: CLIN), the specialty global pharmaceutical company, today announced that the new first-in-class bactericidal, once-daily, injectable antibiotic VIBATIV® (telavancin), is now available to prescribe in Europe for the treatment of adults with nosocomial pneumonia (also known as hospital acquired pneumonia - HAP), including ventilator associated pneumonia (VAP), known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA) when other alternatives are not suitable.



In March 2013, Clinigen, in-licensed V IBATIV® from Theravance, Inc. for commercialization in Europe, however, at that time the European Marketing Authorisation for the drug was suspended due to stopped operations at the previous manufacturer. Clinigen worked closely with a new contract manufacturer and the relevant European authorities to have the suspension lifted. The European Commission (EC) confirmed this in March 2014 enabling Europe-wide, licensed supply to commence. This will be the first time the licensed product will be available in Europe.



VIBATIV® is an innovative treatment for HAP, the most common cause of death among infections acquired in a hospital setting, in that it offers a dual mechanism of action enabling it to kill even drug resistant strains of Staphylococcus aureus.[1]The drug's dual mechanism of action means that even a strain resistant to one of the mechanisms of action may still be affected by the other mechanism, suggesting that VIBATIV® may be less prone to resistance than other antibiotics. HAP caused by MRSA is a considerable unmet need, recognised as a public health priority in the EU. MRSA is estimated to cost EUR380 million every year in extra hospital costs.[2] As a result of these high costs, both economic and human, there is increasing demand for new tools to combat infections caused by drug-resistant bacterial strains and the availability of new antibacterial agents is recognised as playing an important role in treating MRSA.



30-70% of patients who acquire HAP currently die despite early and appropriate treatment, and the condition places a large burden on healthcare systems.[3] There is a limited choice of licensed antibiotic therapies able to treat HAP/VAP caused by MRSA and therefore this launch provides an important, alternative, effective agent in the fight against the growing problem of resistance by bacteria.









"HAP caused by MRSA is often more serious and difficult to treat than similar infections with more drug susceptible strains," said Professor Matteo Bassetti, Professor of Infectious Diseases, School of Medicine and Postgraduate School of Infectious Diseases, University of Udine, Italy. "We are increasingly seeing bacteria acquire resistance to antibiotics previously considered last resort treatments; we need more options to treat these extremely serious infections. The widespread availability of a new and effective antibiotic such as VIBATIV® is therefore very good news for Europe."



"The emergence of so-called 'super bugs' and increasing resistance among microbes to existing antibiotics has been recognised internationally as a major clinical challenge," said Peter George, Group Chief Executive Officer at Clinigen Group plc. "We are therefore extremely proud to be making this potentially life-saving medicine available across Europe for people who may have no other suitable option to fight a life-threatening infection."



- Ends -

Clinigen Group plc Clinigen Launch Antibiotic, Vibativ in Europe
Date : 18/09/2014 @ 16:15
Source : RNS Non regulatory
Stock : Clinigen (CLIN)
Quote : 463.75 2.0 (0.43%) @ 16:20
HOME » LSE » LSE » Clinigen share price

Clinigen Group plc Clinigen Launch Antibiotic, Vibativ in Europe
Share On Facebook Print
Alert
TIDMCLIN

Clinigen Group plc

18 September 2014

Clinigen Group launches New First-in-Class Antibiotic VIBATIV(R) (telavancin) for MRSA related Hospital-Acquired Pneumonia across Europe

Burton-on-Trent, UK - 18 September 2014 - Clinigen Group plc ('Clinigen' or the 'Group') (AIM: CLIN), the specialty global pharmaceutical company, today announced that the new first-in-class bactericidal, once-daily, injectable antibiotic VIBATIV(R) (telavancin), is now available to prescribe in Europe for the treatment of adults with nosocomial pneumonia (also known as hospital acquired pneumonia - HAP), including ventilator associated pneumonia (VAP), known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA) when other alternatives are not suitable.

In March 2013, Clinigen, in-licensed V IBATIV(R) from Theravance, Inc. for commercialization in Europe, however, at that time the European Marketing Authorisation for the drug was suspended due to stopped operations at the previous manufacturer. Clinigen worked closely with a new contract manufacturer and the relevant European authorities to have the suspension lifted. The European Commission (EC) confirmed this in March 2014 enabling Europe-wide, licensed supply to commence. This will be the first time the licensed product will be available in Europe.

VIBATIV(R) is an innovative treatment for HAP, the most common cause of death among infections acquired in a hospital setting, in that it offers a dual mechanism of action enabling it to kill even drug resistant strains of Staphylococcus aureus.([1]) The drug's dual mechanism of action means that even a strain resistant to one of the mechanisms of action may still be affected by the other mechanism, suggesting that VIBATIV(R) may be less prone to resistance than other antibiotics. HAP caused by MRSA is a considerable unmet need, recognised as a public health priority in the EU. MRSA is estimated to cost EUR380 million every year in extra hospital costs.([2]) As a result of these high costs, both economic and human, there is increasing demand for new tools to combat infections caused by drug-resistant bacterial strains and the availability of new antibacterial agents is recognised as playing an important role in treating MRSA.

30-70% of patients who acquire HAP currently die despite early and appropriate treatment, and the condition places a large burden on healthcare systems.([3]) There is a limited choice of licensed antibiotic therapies able to treat HAP/VAP caused by MRSA and therefore this launch provides an important, alternative, effective agent in the fight against the growing problem of resistance by bacteria.

"HAP caused by MRSA is often more serious and difficult to treat than similar infections with more drug susceptible strains," said Professor Matteo Bassetti, Professor of Infectious Diseases, School of Medicine and Postgraduate School of Infectious Diseases, University of Udine, Italy. "We are increasingly seeing bacteria acquire resistance to antibiotics previously considered last resort treatments; we need more options to treat these extremely serious infections. The widespread availability of a new and effective antibiotic such as VIBATIV(R) is therefore very good news for Europe."

"The emergence of so-called 'super bugs' and increasing resistance among microbes to existing antibiotics has been recognised internationally as a major clinical challenge," said Peter George, Group Chief Executive Officer at Clinigen Group plc. "We are therefore extremely proud to be making this potentially life-saving medicine available across Europe for people who may have no other suitable option to fight a life-threatening infection."

- Ends -

About VIBATIV(R) (telavancin)

VIBATIV(R) is a bactericidal, once-daily, injectable lipoglycopeptide antibiotic with a dual mechanism of action whereby VIBATIV(R) both inhibits bacterial cell wall synthesis and disrupts bacterial cell membrane function. VIBATIV(R) is approved in the United States (US) for the treatment of adult patients with (i) complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of Gram-positive bacteria, including Staphylococcus aureus, both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains, and (ii) hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by susceptible isolates of Staphylococcus aureus when alternative treatments are not suitable. In September 2011, the European Commission granted Marketing Authorization for VIBATIV(R) for the treatment of nosocomial pneumonia (hospital-acquired), including ventilator-associated pneumonia, known or suspected to be caused by MRSA when other alternatives are not suitable. VIBATIV(R) was discovered and developed by Theravance, Inc., and transferred to Theravance Biopharma, Inc. in connection with the separation of the two companies in June 2014.

In May 2012, the European Commission suspended Marketing Authorization for VIBATIV(R) because the previous single-source drug product supplier did not meet the current Good Manufacturing Practice ("cGMP") requirements for the manufacture of VIBATIV(R). In March this year the European Commission reinstated the marketing authorisation for VIBATIV(R) as consistent product supply was re-established in accordance with European Commission requirements. Theravance Biopharma Antibiotics, Inc. has granted Clinigen exclusive commercialization rights to VIBATIV(R) in the EU and certain other European countries (including Switzerland and Norway).

For further information, for healthcare professionals please visit www.vibativ.eu

About Clinigen

The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. The Group has three operating businesses; Specialty Pharmaceuticals (Clinigen SP), Clinical Trials Supply (Clinigen CTS), and Global Access Programs (Clinigen GAP).

Clinigen SP is focused on acquiring its own intellectual property in licensed, niche, hospital-only critical care medicines, increasing the value of these medicines by developing new formulations and indications, then registering and marketing them in defined global markets.

For more information, please visit www.clinigengroup.com

Contact Details

Clinigen Group plc Tel: +44 (0) 1283 495 010

Peter George, Group Chief Executive Officer

Shaun Chilton, Chief Operating Officer

Results at the very high end of expectations.

Clinigen Group plc: Underlying EBITDA up 19.8% and EPS up 22% CLINC.L
24 Sep 2014 - 07:10

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20140924:nBw236824a BURTON-ON-TRENT, England--(Business Wire)-- Clinigen Group plc (`Clinigen` or the `Group`, AIM: CLIN), the global specialty pharmaceuticals business, has today published its preliminary results for the 12 months ended 30 June 2014.

Financial highlights

Like for like revenues* on a constant exchange rate basis up 7.5%. Reported revenues up by 3% to £126.6m (FY13: £122.6m)
Gross margin improved in all three operating businesses, increasing to over 30% overall and delivering growth in excess of 17%
Underlying EBITDA** increased by 19.8% to £26.8m (FY13: £22.4m)
Reported pre-tax profits up by 47% to £21.3m (FY13: £14.5m)
Adjusted underlying earnings per share*** up 22% to 24.5 pence (FY13: 20.1 pence) and reported earnings per share up 30% to 19.6 pence (FY13: 15.1 pence)
Cash generation continues to be strong. Net cash of £5.3m combined with the borrowing facility of £35m, provides opportunity for continued expansion.
Final dividend 2.1 pence per share proposed; total dividend 3.1 pence per share (FY13: 2.6 pence per share), up 19%.
Business highlights

Specialty Pharmaceuticals (SP)
Total number of products increased from three to five following the acquisition of two oncology support products; Savene in March 2014 and Ethyol in August 2014.
Suspension of Marketing Authorization lifted for Vibativ and product launched September 2014.
New indications and price increases applied to Foscavir.
Clinical Trials Supply (CTS)
Gross margins returned to 15.1%; deeper penetration of customer base with requests to supply and product sourced both up more than 30%.
New exclusive supply agreement signed.
Global Access Programs (GAP)
58,000 units of drugs shipped to more than 75 countries, an 87% increase, coming from both growth in existing programs and new programs.
Cliniport launched and applied to all programs.
Like for like sales represent revenues adjusted for Foscavir stock fill (£3m) in FY13. ** Underlying EBITDA is defined as earnings before interest, tax, depreciation and amortization excluding share based payments. *** Underlying earnings exclude share based payments, and are adjusted for amortization and associated tax.
Peter George, Chief Executive Officer, Clinigen Group,said "We have had another strong year of growth, with all three operational businesses increasing their contribution.

"Organic business has increased in both CTS and GAP, with a significant improvement in margins for CTS. In SP, we have seen steady growth in in-market sales from Foscavir and revenue streams beginning to come on board from Cardioxane and newly acquired Savene. Vibativ has been revitalized and, in September 2014, launched into the European market. The acquisition of Ethyol brings the total SP drug portfolio to five.

"In the next financial year, the priorities for the Group are two fold; the revitalization of SP`s dexrazoxane asset portfolio (Cardioxane and Savene) and the strengthening of our global capabilities, particularly in pharmerging markets.

"Both strategic goals are important to our long term growth and will support our ambition to become a recognized world leading specialty pharmaceutical company with unrivalled global distribution capability for licensed and unlicenced medicines."

-Ends-

For the full release, please visit the Group`s website at www.clinigengroup.com

What they were expecting......note

2013 (A) 2014 (E) 2015 (E)
EBITDA £19.98m £25.00m £28.69m

OUTPERFORMED

Clinigen Group PLC

Date Rec Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p)

N+1 Singer
22-09-14 BUY 23.49 21.80 3.00 26.66 24.10 3.30
Peel Hunt LLP
18-09-14 BUY 26.05 23.42 3.50 28.97 25.99 4.00
Edison
18-09-14 None 19.40 18.30 2.80 22.20 20.90 3.10
Numis Securities Ltd
17-09-14 BUY 26.00 23.50 3.39 29.00 26.10 4.03
Investec Securities
04-09-14 BUY 25.10 22.61 4.00 29.80 27.45 4.43
Westhouse Securities
10-04-14 BUY

2014 2015
Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p)

Consensus 25.15 22.82 3.29 28.60 25.38 3.77
1 Month Change -0.34 -0.16 -0.15 -0.08 -0.60 -0.35
3 Month Change 0.54 1.24 -0.04 -0.86 -1.10 -0.24

GROWTH

2013 (A) 2014 (E) 2015 (E)
Norm. EPS 107.38% 26.45% 11.22%
DPS % 449.00% 14.51%

INVESTMENT RATIOS

2013 (A) 2014 (E) 2015 (E)
EBITDA £19.98m £25.00m £28.69m
EBIT £18.10m £m £m
Dividend Yield 0.13% 0.71% 0.81%
Dividend Cover 30.08x 6.93x 6.73x
PER 25.79x 20.39x 18.34x
PEG 0.24f 0.77f 1.64f
Net Asset Value PS 14.21p 78.80p 98.60p

CLIN CLINIGEN

What Brokers were expecting, I bet we get some upgrades and updates later today....

Date Broker Recommendation Price Old target price New target price Notes
02 Sep Oriel Securities Buy 458.50 - 650.00 Reiterates
26 Aug N+1 Singer Buy 458.50 439.00 488.00 Reiterates
20 Aug Investec Buy 458.50 497.00 512.00 Reiterates
20 Aug Numis Buy 458.50 650.00 650.00 Reiterates

A group analyst briefing will be held at 09:30am on Wednesday, 24 September 2014 at the offices of Instinctif Partners, 65 Gresham Street, London EC2V 7NQ.

An audio replay file will be made available shortly afterwards via the Group's website: www.clinigengroup.com.

A wall of Blue Buys for CLIN after todays results......Broker update and upgrades to come after analyst meeting 9.30

">

First of the Brokers......

24 Sep 2014 Clinigen Group CLIN N+1 Singer Buy 466.00 456.00 488.00 488.00 Retains

24 Sep 2014 Clinigen Group CLIN Numis Buy 465.50 456.00 650.00 650.00 Reiterates

650p SP TARGET

24 Sep 2014 Clinigen Group CLIN Oriel Securities Buy 463.50 456.00 650.00 650.00 Reiterates

SP target 650p

Peel Hunt few days ago, buy tp 710p

I.C. today

Clinigen still clinical
When drugs fail to obtain licenses or are pulled off the market, clinicians can miss out on vital elements of medical treatment. Clinigen (CLIN) fills this gap, acquiring, revitalising and then distributing the drugs. This focus helped it record a 20 per cent rise in underlying cash profits for the year to June.
Sales at Clinigen’s key clinical trials supply division fell 5 per cent to £84m, reflecting a one-off bump in antiviral sales in 2013. But it did record a 45 per cent increase in supply requests, as the company widened its market share, so sales should rebound. It also signed an exclusive supply agreement for an oncology drug with an international pharmaceutical company.
Clinigen’s specialty pharmaceuticals division grew its product range by acquiring Savene and Ethyol, two oncology support products. That should help to compensate for slowing sales of Foscavir now its revitalisation is largely complete. Clinigen also convinced European regulators to lift the suspension order on its injectable antibiotic Vibativ, which combats hospital-acquired pneumonia.
Meanwhile, sales surged by more than half at its global access programs segment, as it shipped 58,000 drug units – up 87 per cent – to over 75 countries. The division also added AstraZeneca (AZN) and Eisai to its client list.
Broker Numis Securities expects pre-tax profit of £29m, giving EPS of 26.1p, rising to £35m and 31.6p in 2015-16.
C Clinigen’s growing product range and diversified business model should serve investors well. Its shares trade at 18 times forecast earnings – a discount to the sector average of 21. We reiterate our buy tip. TM

Clinigen Group plc Receives FDA Award

RNS


RNS Number : 8240S

Clinigen Group plc

29 September 2014












Clinigen Group plc Receives FDA's First Ever Drug Shortage Assistance Award



Burton-on-Trent, UK - 29 September 2014 - Clinigen Group plc ('Clinigen' or the 'Group', AIM:CLIN) the global specialty pharmaceutical company, today announces that it has received the first Drug Shortage Assistance Award from the US Food and Drug Administration (FDA) in recognition of its contribution in addressing a US shortage of Foscavir® (foscarnet sodium) injection.



Clinigen's efforts related to the US shortage included making Foscavir® available on a named patient basis whilst acquiring the new drug application and submitting post-approval supplements to restart manufacturing with acceptable compliance records. These actions by Clinigen resolved a critical drug shortage affecting patients.



This award also recognizes companies for their commitment to public health, as well as to quality manufacturing and is the first time the award has been made by the FDA.



Peter George, Chief Executive Officer, Clinigen Group, said: "To be the recipient of this new award from the FDA is a great honor and absolutely reflects Clinigen's mission to ensure that the right drug reaches the right patient at the right time. Since acquiring Foscavir® from AstraZeneca in 2010, we have worked hard to expand the indications and markets for the drug to increase the number of patients who can benefit. It is a real compliment that the FDA is committed to working with companies, like Clinigen, to prevent and mitigate drug shortages."



Drug shortages pose a substantial public health threat, delaying, and in some cases even denying, critically needed care for patients. Working with drug manufacturers, the FDA helped prevent over 280 drug shortages in 2012 and 170 in 2013. There were 44 new drug shortages in 2013, down from 117 new drug shortages in 2012. Two key prevention strategies have helped drive this significant decrease in new shortages: 1) early notification and 2) a focus on quality manufacturing.



- Ends -

Ex dividend Thurs 16 Oct 2.1p

Jim Slater: Escape death taxes with my perfect portfolio of shares

Shares listed on the Aim market are exempt from inheritance tax. Our expert stock picker Jim Slater names three of the best


My next recommendation for your IHT-friendly portfolio is Clinigen Group at 507p. This speciality global pharmaceuticals company, headquartered in Britain and with offices in America and Japan, floated on the stock market in late 2012.

Since then, with the help of astute acquisitions and organic growth, the company has performed very well – profits have risen from 8.7p per share in 2012 to a predicted 26p for 2015.

The group has three main divisions, one of which, “global access programs”, has signed significant contracts with two leading companies, AstraZeneca and Boehringer Ingelheim, and seen its sales rise by 54pc last year.

However, what interests me now is that the main focus of the Clinigen story is shifting to the “speciality pharma” division, which makes high gross profit margins and has developed from one product at the time of the flotation to five products today, with more planned. Two of its products are in “anti-infectives” and three are in oncology support.

In particular, two of the latter, Cardioxane and Ethyol, have strong potential for revitalisation – although before I get carried away I must confess that, even though my wife tells me I am a bit of a hypochondriac, I am not an expert on drugs.

I am therefore happy to rely on the enthusiasm of the stockbrokers’ technical analysts who follow Clinigen and their favourable view of the company’s drugs portfolio.

Now for the numbers. According to brokers Numis, Clinigen’s estimated p/e ratio for next year is about 19.5, falling to about 16 in 2016 and then to 13.3. Numis expects profit growth percentages in the 20s in 2016 and 2017 with further acquisitions adding “incremental upside” to give a forward Peg ratio of just under 1.

Both brokers make the point that the company is acquisitive, produces very strong cash flows and has a substantial amount of cash in the bank, so they confidently expect more acquisitions.

Certainly Numis and Peel Hunt have high hopes for its future, with price targets of 650p for Numis and 717p for Peel Hunt. The three other brokers that cover Clinigen also rate the shares as a “strong buy”.

During recent market weakness – last month’s “flash crash” – I managed to buy more than £1.5m worth of Clinigen shares at an average price of about 470p.

However, I should warn you that the market in them can be narrow at times, so if you decide to buy I suggest that you set a firm limit with your broker and if necessary be prepared to wait a few days for your order to be filled.





http://www.telegraph.co.uk/finance/personalfinance/investing/shares-and-stock-tips/11217454/Jim-Slater-Escape-inheritance-tax-with-my-perfect-portfolio-of-shares.html

Signal Update

Our system’s recommendation today is to STAY LONG. The previous BUY signal was issued on 04/11/2014, 14 days ago, when the stock price was 480.5000. Since then CLIN.L has risen by +13.84%.

Market Outlook

The market is uncertain with a negative tilt. The traders seem to be in disagreement. The negative sentiment, however, is increasing as evident from the last bearish pattern. So, it is better to be on alert.


http://www.britishbulls.com/SignalPage.aspx?lang=en&Ticker=CLIN.L

Half year trading update
RNS
RNS Number : 2048C
Clinigen Group plc
15 January 2015



Half year trading update

Burton-on-Trent, UK - 15 January 2015 - Clinigen Group plc ('Clinigen' or the 'Group', AIM: CLIN), the specialty global pharmaceutical company, today provides a half year update for the six months ended
31 December 2014.



The Group continues to perform strongly, in line with the Board's expectations:

· Revenues at £72.6m are up 17% on H1 FY14 (21% on a constant exchange rate basis)

· Gross profit is up 11%, with overall margins at 30%

· Net cash has more than doubled to £12.9m from £5.3m at 30 June 2014



Revenue growth over the period has been driven by a combination of significant organic and new customer growth in CTS - demonstrating the progress of Clinigen CTS towards global leadership - with the additional contribution from new product acquisitions within Clinigen SP (Savene and Ethyol). Also within SP, Foscavir in-market sales are up 5%, in line with disease treatment activity.



The Group's CTS activity measures: growth in current customers, number of customers, number of products shipped and the sales pipeline, all continue to grow.



The number of units shipped by GAP, the primary measure of growth in that business, continues to increase and a number of new programs will go live in Q3 FY15. H1 FY15 GAP revenues were, as expected, affected by the closure of the French Enzalutamide program, but this also led to an improvement in gross margin, returning to expected 40% levels from H1 FY14 at 28%.



The Group continues to evaluate new opportunities for both product acquisitions and global expansion.



Peter George, Chief Executive Officer, Clinigen Group said,



"I am really proud of the team's first half performance; all three operating businesses have contributed to strong trading. I am particularly pleased with the CTS performance and the early contributions from new product acquisitions.



"The integration of the new products acquired in FY14 and H1 FY15 continues on track and I expect the current investment in the revitalization plans to start to have a positive impact during FY16.



"This strong half year performance is in line with the Board's expectations and puts us in a good position to meet our full year targets."

-Ends-

UPDATE - Clinigen first half revenues up 17%, boosted by clinical trials supply arm and new products

By Ian Lyall

January 15 2015, 11:41am
Clinigen said the financials were in line with expectations, leaving the business on track to meet full-year forecasts.
Clinigen said the financials were in line with expectations, leaving the business on track to meet full-year forecasts.


Clinigen (LON:CLIN) said it performed strongly in the first half of its financial year as its clinical trials supply business (CTS) cemented its place as a global leader in the sector.

The specialty pharma group’s trading in the six months to the end of last year was also boosted by the contribution from new additions to the portfolio, and two in particular: oncology products Savene and Ethyol.

Revenues rose 17% year-on-year to almost £73mln; gross profit was up 11%, margins ahead 30% and net cash more than doubled at £12.9mln.

Clinigen said the financials were in line with expectations, leaving the business on track to meet full-year forecasts.

Chief executive Peter George told investors: "I am really proud of the team's first half performance; all three operating businesses have contributed to strong trading.

“I am particularly pleased with the CTS performance and the early contributions from new product acquisitions.”

George added that the integration of the new products acquired recently is “on track” and the current investment in revitalising them will have a “positive impact” next financial year.

Analysts at Peel Hunt said the overall result appears slightly ahead at the top line, at a lower gross margin, with the result in line at the gross profit level.

“With cash now mounting on the balance sheet, the firepower to add to the portfolio is there with the ambition to accelerate Clinigen’s global footprint growing,” added the broker.

Peel Hunt has a 717p share price target.

Shares are currently trading at 495p.